Search results
Found 10052 matches for
Congratulations to Professor Jan Rehwinkel, a group leader in the MRC Human Immunology Unit, who was named last week as one of 25 new EMBO Young Investigators.
Sharma Group: Mechanistic T Cell Genomics
Our research team is focused on uncovering the mechanisms that govern T cell signaling, with the goal of precisely engineering immune cells for immunotherapies.
Vyas Group: Biology and Treatment of Human Myeloid Cancers
We aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.
Skin Immunology Group
The aim of the group is to understand, at the molecular and cellular level, the role of human cutaneous immune responses in mechanisms of disease, treatment and vaccination. We have a particular focus on T cells which recognise inflammatory lipids presented by CD1a. As well as contributing to an understanding of disease pathogenesis, we aim to translate our findings to changes in clinical practice.
RAMADAN GROUP
DNA Damage Response
Dong Group | T cell responses against Viruses & Cancer
Our group focuses on determining the factors which affect T cells both in the control of viral infection and in the development of cancer.
Koohy Group: Machine Learning and Integrative Approaches in Immunology
We would like to understand the functional and molecular mechanisms of the immune system in various immunologically important conditions such as cancer, infection, autoimmune disease as well as ageing. We have a special interest in computational cancer immunotherapy such as antigen presentation, neo-antigen identification and T cell recognition of neo-antigens as well as interrogating the immune response to personalized vaccines from neo-antigens.
de Bruijn Group: Developmental Haematopoiesis
We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.
Psaila Group: Megakaryocytes, Platelets and Myeloproliferative Neoplasms
We focus on four key areas: (1) Dissecting how blood cancers create 'self-reinforcing' niches that promote clonal expansion and protect malignant clones from immunotherapies; (2) Development and application of human bone marrow organoids to study normal and malignant haematopoiesis and validate targets in a relevant tissue microenvironment; (3) Developing novel strategies to selectively target cancer stem cells and pathological megakaryocytes in myelofibrosis, a severe bone marrow malignancy; (4) Understanding our recent discovery that platelets contain a repertoire of DNA fragments sequestered from cell free DNA, and confirming clinical utility for cancer detection and for pre-natal diagnosis.
Simmons Group: Intestinal Immunity in Health and Disease
We define how the immune system functions in the intestine to promote health. We uncover the immune pathogenesis of intestinal diseases such as inflammatory bowel disease to develop better ways to treat these disorders.
Chakraverty Group: Haematopoietic Transplantation and Immunotherapy
Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.